Ningbo Menovo Pharmaceutical Co., Ltd.
Symbool: 603538.SS
SHH
14.58
CNYMarktprijs vandaag
-165.8310
Koers/Winst Verhouding
-26.5330
Koers/Winst Groei Verhouding
3.09B
MRK Kapitalisatie
- 0.01%
DIV Rendement
Ningbo Menovo Pharmaceutical Co., Ltd. (603538-SS) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 724.7 | 1009.3 | 793.2 | |||||||||||||
balance-sheet.row.short-term-investments | 0 | 268.6 | 217.4 | 371.4 | |||||||||||||
balance-sheet.row.net-receivables | 0 | 320.7 | 231.5 | 266.2 | |||||||||||||
balance-sheet.row.inventory | 0 | 612.6 | 594.4 | 579.7 | |||||||||||||
balance-sheet.row.other-current-assets | 0 | 50.3 | 59.2 | 63.4 | |||||||||||||
balance-sheet.row.total-current-assets | 0 | 1759.4 | 1894.4 | 1702.4 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1900.3 | 1801.9 | 1614.7 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 22.7 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 206.2 | 172.5 | 201.7 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 206.2 | 172.5 | 224.4 | |||||||||||||
balance-sheet.row.long-term-investments | 0 | 315.3 | 82.7 | -51.8 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 42.7 | 123.1 | 33.3 | |||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 199.6 | 344.8 | 478.5 | |||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 2664.1 | 2525.1 | 2299.1 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 0 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.account-payables | 0 | 553.7 | 499.3 | 389.1 | |||||||||||||
balance-sheet.row.short-term-debt | 0 | 542.8 | 497 | 505 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 25.5 | 72.1 | 34.6 | |||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 759.6 | 705.6 | 755.3 | |||||||||||||
Deferred Revenue Non Current | 0 | 81.5 | 70.6 | 48.7 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 0 | 2 | 171 | 3.9 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 859.6 | 884 | 876.2 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 15.7 | 30.3 | 28 | |||||||||||||
balance-sheet.row.total-liab | 0 | 2237.8 | 2246.2 | 2023 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 36.3 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0 | 213.4 | 213.4 | 151.3 | |||||||||||||
balance-sheet.row.retained-earnings | 0 | 1210.6 | 1234.3 | 937.4 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 75.6 | 101.4 | 77.6 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 560.4 | 535.9 | 585.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2096.3 | 2085 | 1751.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 89.4 | 88.3 | 227 | |||||||||||||
balance-sheet.row.total-equity | 0 | 2185.7 | 2173.2 | 1978.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||
Total Investments | 0 | 315.3 | 300.1 | 319.6 | |||||||||||||
balance-sheet.row.total-debt | 0 | 1302.5 | 1202.6 | 1260.4 | |||||||||||||
balance-sheet.row.net-debt | 0 | 846.4 | 410.7 | 838.6 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 367.6 | 158.1 | 173.1 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 101.8 | 98.9 | 85 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | -40.2 | -21 | 18.4 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | 24.7 | 5.3 | 10.9 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | -85.4 | -62.2 | -2.8 | ||||||||||||
cash-flows.row.account-receivables | 0 | -213.6 | -50.9 | -28.2 | ||||||||||||
cash-flows.row.inventory | 0 | -183 | -124.7 | -83 | ||||||||||||
cash-flows.row.account-payables | 0 | 351.4 | 134.4 | 63.3 | ||||||||||||
cash-flows.row.other-working-capital | 0 | -40.2 | -21 | 45.1 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | -91.4 | 41.5 | -32.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 487.9 | -47.1 | 0.5 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | -713.9 | -1640.5 | -865 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 902.5 | 1562.2 | 693.5 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | -54.6 | 52 | 3.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 50.3 | -603.3 | -479 | ||||||||||||
cash-flows.row.debt-repayment | 0 | -749.5 | -788.1 | -802.5 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0.2 | 0.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | -0.5 | ||||||||||||
cash-flows.row.dividends-paid | 0 | -50 | -13.8 | -41 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 621.1 | 1385.1 | 981.9 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -178.5 | 583.1 | 138.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 14.6 | -2.3 | -2 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | 163.4 | 198.2 | -91 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 537 | 373.6 | 174.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 373.6 | 175.4 | 265.5 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | 277 | 220.6 | 251.6 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | -294.7 | -309.3 | -60.1 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1216.5 | 1457 | 1258.1 | |||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 840.9 | 872.8 | 788.9 | |||||||||||||
income-statement-row.row.gross-profit | 0 | 375.6 | 584.2 | 469.2 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 0 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.operating-expenses | 0 | 291.2 | 341.4 | 281 | |||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1132.1 | 1214.2 | 1069.9 | |||||||||||||
income-statement-row.row.interest-income | 0 | 5.5 | 5.7 | 2.2 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 118.5 | 128.3 | 124.1 | |||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | 0 | 18.7 | 405.3 | 187.9 | |||||||||||||
income-statement-row.row.income-before-tax | 0 | 8 | 384.2 | 180.3 | |||||||||||||
income-statement-row.row.income-tax-expense | 0 | -8.2 | 16.5 | 22.2 | |||||||||||||
income-statement-row.row.net-income | 0 | 11.6 | 338.9 | 142.5 |
Vaak gestelde vragen
Wat is Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) totale activa?
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) totale activa is 4423515920.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.319.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.014.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.013.
Wat is Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) nettowinst (netto-inkomen)?
De nettowinst is 11585592.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 1302458461.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 291175048.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.